NEW YORK (GenomeWeb News) - AstraZeneca has signed a three-year agreement for BioWisdom’s Safety Intelligence Program, an initiative to develop an “intelligence system” to analyze drug safety and toxicity data for use in drug discovery and development.
 
BioWisdom said AstraZeneca is its first partner for the program, and as such takes a place on the firm’s SIP advisory board. 
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.